Home Stocks LYRA Lyra Therapeutics Inc (NASDAQ: LYRA) Healthcare · Biotechnology
$0.03
Last close · Nov 17, 2026 · NASDAQ USD
The Quantellect read. Short interest is 1.43% of float with a 5.37% borrow fee. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Mixed valuation signals P/S 0.8× vs peer median 13.9×
Trend Below both averages $0.03 vs $0.27 and $1.28 · as of Nov 17, 2026
Short interest 1.4% of float FINRA settlement Oct 30, 2026
SMA 10 $0.16 SMA 20 $0.16 SMA 50 $0.27 SMA 200 $1.28
Nov 17, 2026 O $0.03 H $0.03 L $0.03 C $0.03 Vol 266
×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date May 18, 2026 ET Last date Nov 17, 2026 ET Open $0.70 High $0.88 Low $0.00 Close $0.03 Volume 682,353 Plotted bars 78
Plotted OHLCV bars May 18, 2026 ET · Open $0.70 · High $0.70 · Low $0.65 · Close $0.65 · Volume 6,179 May 19, 2026 ET · Open $0.65 · High $0.75 · Low $0.65 · Close $0.74 · Volume 7,111 May 20, 2026 ET · Open $0.75 · High $0.75 · Low $0.73 · Close $0.73 · Volume 11,033 May 21, 2026 ET · Open $0.70 · High $0.75 · Low $0.70 · Close $0.70 · Volume 2,496 May 22, 2026 ET · Open $0.88 · High $0.88 · Low $0.65 · Close $0.75 · Volume 18,321 May 26, 2026 ET · Open $0.70 · High $0.75 · Low $0.70 · Close $0.70 · Volume 3,159 May 27, 2026 ET · Open $0.74 · High $0.78 · Low $0.70 · Close $0.78 · Volume 6,131 May 28, 2026 ET · Open $0.72 · High $0.72 · Low $0.70 · Close $0.70 · Volume 1,278 May 29, 2026 ET · Open $0.72 · High $0.75 · Low $0.72 · Close $0.74 · Volume 2,838 Jun 1, 2026 ET · Open $0.75 · High $0.75 · Low $0.70 · Close $0.70 · Volume 1,842 Jun 2, 2026 ET · Open $0.70 · High $0.75 · Low $0.70 · Close $0.70 · Volume 4,131 Jun 3, 2026 ET · Open $0.70 · High $0.70 · Low $0.65 · Close $0.66 · Volume 20,831 Jun 4, 2026 ET · Open $0.70 · High $0.70 · Low $0.69 · Close $0.69 · Volume 11,097 Jun 5, 2026 ET · Open $0.70 · High $0.71 · Low $0.70 · Close $0.70 · Volume 1,058 Jun 8, 2026 ET · Open $0.70 · High $0.70 · Low $0.70 · Close $0.70 · Volume 5,288 Jun 9, 2026 ET · Open $0.65 · High $0.80 · Low $0.65 · Close $0.80 · Volume 2,058 Jun 10, 2026 ET · Open $0.70 · High $0.75 · Low $0.55 · Close $0.60 · Volume 88,159 Jun 11, 2026 ET · Open $0.75 · High $0.75 · Low $0.60 · Close $0.60 · Volume 3,102 Jun 12, 2026 ET · Open $0.60 · High $0.71 · Low $0.55 · Close $0.55 · Volume 40,506 Jun 15, 2026 ET · Open $0.55 · High $0.65 · Low $0.55 · Close $0.65 · Volume 3,622 Jun 16, 2026 ET · Open $0.63 · High $0.69 · Low $0.60 · Close $0.69 · Volume 1,377 Jun 18, 2026 ET · Open $0.60 · High $0.68 · Low $0.60 · Close $0.68 · Volume 232 Jun 22, 2026 ET · Open $0.60 · High $0.65 · Low $0.44 · Close $0.57 · Volume 84,579 Jun 23, 2026 ET · Open $0.65 · High $0.65 · Low $0.56 · Close $0.56 · Volume 10,725 Jun 24, 2026 ET · Open $0.58 · High $0.58 · Low $0.58 · Close $0.58 · Volume 309 Jun 26, 2026 ET · Open $0.60 · High $0.60 · Low $0.60 · Close $0.60 · Volume 355 Jun 29, 2026 ET · Open $0.60 · High $0.60 · Low $0.60 · Close $0.60 · Volume 756 Jun 30, 2026 ET · Open $0.64 · High $0.70 · Low $0.60 · Close $0.70 · Volume 22,214 Jul 1, 2026 ET · Open $0.62 · High $0.63 · Low $0.60 · Close $0.62 · Volume 6,053 Jul 2, 2026 ET · Open $0.65 · High $0.71 · Low $0.65 · Close $0.71 · Volume 178 Jul 7, 2026 ET · Open $0.55 · High $0.65 · Low $0.50 · Close $0.60 · Volume 148,958 Jul 8, 2026 ET · Open $0.60 · High $0.60 · Low $0.51 · Close $0.51 · Volume 15,603 Jul 9, 2026 ET · Open $0.51 · High $0.54 · Low $0.51 · Close $0.54 · Volume 10,755 Jul 10, 2026 ET · Open $0.54 · High $0.54 · Low $0.54 · Close $0.54 · Volume 280 Jul 13, 2026 ET · Open $0.48 · High $0.50 · Low $0.48 · Close $0.48 · Volume 11,082 Jul 14, 2026 ET · Open $0.59 · High $0.65 · Low $0.31 · Close $0.37 · Volume 47,246 Jul 15, 2026 ET · Open $0.55 · High $0.58 · Low $0.38 · Close $0.52 · Volume 9,248 Jul 16, 2026 ET · Open $0.30 · High $0.58 · Low $0.30 · Close $0.57 · Volume 3,780 Jul 17, 2026 ET · Open $0.45 · High $0.52 · Low $0.36 · Close $0.52 · Volume 12 Jul 23, 2026 ET · Open $0.00 · High $0.52 · Low $0.00 · Close $0.52 · Volume 415 Jul 27, 2026 ET · Open $0.50 · High $0.50 · Low $0.50 · Close $0.50 · Volume 2,000 Jul 29, 2026 ET · Open $0.48 · High $0.48 · Low $0.48 · Close $0.48 · Volume 204 Aug 5, 2026 ET · Open $0.45 · High $0.45 · Low $0.11 · Close $0.40 · Volume 1,131 Aug 7, 2026 ET · Open $0.35 · High $0.35 · Low $0.33 · Close $0.34 · Volume 990 Aug 10, 2026 ET · Open $0.40 · High $0.40 · Low $0.27 · Close $0.28 · Volume 11,261 Aug 11, 2026 ET · Open $0.25 · High $0.25 · Low $0.25 · Close $0.25 · Volume 109 Aug 12, 2026 ET · Open $0.25 · High $0.25 · Low $0.25 · Close $0.25 · Volume 141 Aug 13, 2026 ET · Open $0.15 · High $0.25 · Low $0.15 · Close $0.25 · Volume 832 Aug 17, 2026 ET · Open $0.00 · High $0.25 · Low $0.00 · Close $0.24 · Volume 621 Aug 18, 2026 ET · Open $0.02 · High $0.04 · Low $0.02 · Close $0.04 · Volume 5,235 Aug 19, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 555 Aug 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 815 Aug 24, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 119 Aug 25, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 1,046 Aug 31, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 1,011 Sep 2, 2026 ET · Open $0.01 · High $0.20 · Low $0.01 · Close $0.20 · Volume 456 Sep 8, 2026 ET · Open $0.03 · High $0.19 · Low $0.03 · Close $0.19 · Volume 224 Sep 9, 2026 ET · Open $0.20 · High $0.20 · Low $0.20 · Close $0.20 · Volume 110 Sep 16, 2026 ET · Open $0.03 · High $0.20 · Low $0.03 · Close $0.20 · Volume 2,206 Sep 21, 2026 ET · Open $0.05 · High $0.20 · Low $0.05 · Close $0.20 · Volume 1,118 Sep 22, 2026 ET · Open $0.05 · High $0.20 · Low $0.05 · Close $0.20 · Volume 600 Sep 24, 2026 ET · Open $0.03 · High $0.20 · Low $0.03 · Close $0.03 · Volume 2,004 Sep 25, 2026 ET · Open $0.20 · High $0.20 · Low $0.20 · Close $0.20 · Volume 213 Sep 30, 2026 ET · Open $0.03 · High $0.03 · Low $0.03 · Close $0.03 · Volume 341 Oct 1, 2026 ET · Open $0.03 · High $0.15 · Low $0.03 · Close $0.15 · Volume 2,678 Oct 2, 2026 ET · Open $0.15 · High $0.15 · Low $0.15 · Close $0.15 · Volume 348 Oct 5, 2026 ET · Open $0.14 · High $0.19 · Low $0.14 · Close $0.19 · Volume 317 Oct 8, 2026 ET · Open $0.03 · High $0.20 · Low $0.03 · Close $0.20 · Volume 2,102 Oct 9, 2026 ET · Open $0.03 · High $0.19 · Low $0.03 · Close $0.19 · Volume 2,100 Oct 12, 2026 ET · Open $0.00 · High $0.20 · Low $0.00 · Close $0.19 · Volume 1,637 Oct 13, 2026 ET · Open $0.05 · High $0.19 · Low $0.05 · Close $0.19 · Volume 420 Oct 19, 2026 ET · Open $0.03 · High $0.19 · Low $0.03 · Close $0.19 · Volume 4,321 Oct 27, 2026 ET · Open $0.03 · High $0.19 · Low $0.03 · Close $0.19 · Volume 10,110 Nov 2, 2026 ET · Open $0.03 · High $0.19 · Low $0.03 · Close $0.19 · Volume 403 Nov 5, 2026 ET · Open $0.03 · High $0.19 · Low $0.03 · Close $0.19 · Volume 401 Nov 12, 2026 ET · Open $0.00 · High $0.20 · Low $0.00 · Close $0.19 · Volume 1,372 Nov 16, 2026 ET · Open $0.03 · High $0.03 · Low $0.03 · Close $0.03 · Volume 8,139 Nov 17, 2026 ET · Open $0.03 · High $0.03 · Low $0.03 · Close $0.03 · Volume 266 Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of Nov 18, 2026, 8:46 PM ET
Initial 6M price range summary Range 6M First close $0.65 Last close $0.03 High $0.88 Low $0.00 Volume 682,353
Open — Historical · Nov 17, 2026
Previous close — Historical · Nov 17, 2026
Day range — Historical · Nov 17, 2026
52-week range — Through Nov 18, 2026
Volume — Historical · Nov 17, 2026
Average volume (30 calendar days, 7 sessions) 3.57K Through Nov 18, 2026
Market cap $337.23K
P/E (TTM) negative earnings —
Forward P/E —
EPS (TTM) stale vendor snapshot —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) 0.01
Price history LYRA · nasdaq · USD
Last completed session: Nov 17, 2026
Split-adjusted · volume in shares
Missing sessions: Nov 3, 2026, Nov 4, 2026, Nov 6, 2026, Nov 9, 2026, Nov 10, 2026, Nov 11, 2026, Nov 13, 2026, Nov 18, 2026
November 2026 · 5 completed sessions Date Open High Low Close Change Volume Nov 17 0.03 0.03 0.03 0.03 0.000.00% 266 Open 0.03 High 0.03 Low 0.03 Nov 16 0.03 0.03 0.03 0.03 — 8,139 Open 0.03 High 0.03 Low 0.03 Nov 12 0.0004 0.195 0.0004 0.19 — 1,372 Open 0.0004 High 0.195 Low 0.0004 Nov 5 0.03 0.19 0.03 0.19 — 401 Open 0.03 High 0.19 Low 0.03 Nov 2 0.03 0.19 0.03 0.19 — 403 Open 0.03 High 0.19 Low 0.03
Notable price movement Sessions where the close moved at least twice its average daily move of the prior 20 sessions (minimum 3%), or 10% or more.
Nov 16
$0.03 −84.21%
Trading volume was 2.5 times the 30-day average, with 8.14K shares traded.
Oct 5
$0.19 +26.67%
Trading volume was 0.3 times the 30-day average, with 317 shares traded.
Oct 1
$0.15 +400.00%
Trading volume was 3.3 times the 30-day average, with 2.68K shares traded.
Options flow — · Options flow not available
Q Score — · Q Score not available
How LYRA compares with its industry Against 592 other US-listed Biotechnology stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Points of cautionOne-month return was -84.2%, with only 1% of 567 peers reporting a lower value.Peer median −13.8% · As of Nov 16, 2026 Latest-quarter year-over-year sales growth was -96.7%, with only 10% of 592 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Valuation Mixed valuation signals
Metric LYRA Peer median
Profitability Profitability metrics are lower than most peers.
Metric LYRA Peer median
Gross margin — 78.4%
Not ranked: only 247 of 592 peers report it
Operating margin — 0.0%
Not ranked: only 443 of 592 peers report it
Net margin 0.0% 0.0%
Higher than 19% of 583 peers
Return on equity — −67.9%
Not ranked: only 555 of 592 peers report it
Growth Growth metrics are lower than most peers.
Metric LYRA Peer median
Quarterly sales growth, year over year −96.7% 0.0%
Bottom 10% of peers Higher than 10% of 592 peers
5-year sales growth rate — 11.3%
Not ranked: only 140 of 592 peers report it
Balance sheet Not enough peers report balance sheet metrics for a group comparison.
Metric LYRA Peer median
Current ratio — 5.01
Not ranked: only 499 of 592 peers report it
Debt/equity (total borrowings) — 0.23
Not ranked: only 117 of 592 peers report it
Momentum Not enough peers report returns for a group comparison.
Metric LYRA Peer median
1-year return — −28.4%
Not ranked: only 523 of 592 peers report it
6-month return — −26.6%
Not ranked: only 546 of 592 peers report it
3-month return — −29.8%
Not ranked: only 559 of 592 peers report it
How to read this The dot marks where LYRA ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026
Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history EPS, last 8 quarters −20.00 −15.00 −10.00 −5.00 0.00 Q1 ’24 Q2 ’24 Q3 ’24 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Annual 2025 — −$18.62 —
Q3 2025 — −$3.38 —
Q2 2025 — −$5.51 —
Q1 2025 — −$0.13 —
Annual 2024 −$0.13 −$1.43 —
Q3 2024 −$10.25 −$0.18 —
Q2 2024 −$16.40 −$0.74 —
Q1 2024 −$13.40 −$0.35 —
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.
Date Type Who Action Amount Source
Jan 6, 2026 Insider sell Cavalier Jason Sell $2.6K Form 4 Jan 6, 2026 Insider sell Palasis Maria Sell $5.7K Form 4 Nov 13, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $12.5K Form 4 Nov 13, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $111.5K Form 4 Nov 12, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $3.6K Form 4 Nov 12, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $31.9K Form 4 Nov 11, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $2.3K Form 4 Nov 11, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $20.6K Form 4 Nov 10, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $8.5K Form 4 Nov 10, 2025 Insider sell PERCEPTIVE ADVISORS LLC / PERCEPTIVE LIFE SCIENCES MASTER FUND LTD / Perceptive LS (A), LLC / EDELMAN JOSEPH Sell $75.5K Form 4 All smart-money activity → Company profile Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic
CEO —
Headquarters Watertown, MA, United States
Employees 27
IPO date May 1, 2020
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history EPS, last 8 quarters −20.00 −15.00 −10.00 −5.00 0.00 Q1 ’24 Q2 ’24 Q3 ’24 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Annual 2025 — −$18.62 —
Q3 2025 — −$3.38 —
Q2 2025 — −$5.51 —
Q1 2025 — −$0.13 —
Annual 2024 −$0.13 −$1.43 —
Q3 2024 −$10.25 −$0.18 —
Q2 2024 −$16.40 −$0.74 —
Q1 2024 −$13.40 −$0.35 —
Company profile Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic
CEO —
Headquarters Watertown, MA, United States
Employees 27
IPO date May 1, 2020
Sector Healthcare
Industry Biotechnology